StemGen, Inc. Logo

StemGen, Inc.

SGNI

(1.5)
Stock Price

0,10 USD

-142.9% ROA

0% ROE

-7.95x PER

Market Cap.

4.567.110,00 USD

-42.22% DER

0% Yield

0% NPM

StemGen, Inc. Stock Analysis

StemGen, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

StemGen, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

ROE surpassing expectations (47.29%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

2 PBV

With a remarkably low PBV ratio (-3.42x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a low debt to equity ratio (-42%), which means it has a small amount of debt compared to the ownership it holds

4 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

5 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

6 Buffet Intrinsic Value

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

7 ROA

The stock's ROA (-142.9%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Revenue Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

9 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

10 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Graham Number

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

StemGen, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

StemGen, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Sell
3 RSI Buy
4 Stoch RSI Buy

StemGen, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

StemGen, Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 22.058 100%
2020 19.350 -13.99%
2021 39.000 50.38%
2022 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

StemGen, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

StemGen, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 209.886
2007 90.000 -133.21%
2008 50.000 -80%
2009 99.850 49.92%
2010 37.726 -164.67%
2011 41.946 10.06%
2012 27.710 -51.37%
2013 60.202 53.97%
2014 51.183 -17.62%
2015 339.085 84.91%
2016 341.228 0.63%
2017 0 0%
2018 32.325 100%
2019 196.734 83.57%
2020 58.475 -236.44%
2021 139.993 58.23%
2022 599.552 76.65%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

StemGen, Inc. EBITDA
Year EBITDA Growth
2006 -595.282
2007 -432.287 -37.71%
2008 -50.000 -764.57%
2009 -99.850 49.92%
2010 -37.726 -164.67%
2011 -41.946 10.06%
2012 -27.710 -51.37%
2013 -27.702 -0.03%
2014 -51.183 45.88%
2015 -339.085 84.91%
2016 -341.228 0.63%
2017 7.549 4620.17%
2018 -32.325 123.35%
2019 -183.186 82.35%
2020 -47.697 -284.06%
2021 -131.447 63.71%
2022 -616.356 78.67%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

StemGen, Inc. Gross Profit
Year Gross Profit Growth
2006 -187.851
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 13.548 100%
2020 10.778 -25.7%
2021 8.546 -26.12%
2022 -16.804 150.86%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

StemGen, Inc. Net Profit
Year Net Profit Growth
2006 281.531
2007 -410.000 168.67%
2008 -50.000 -720%
2009 -111.762 55.26%
2010 -55.201 -102.46%
2011 -59.044 6.51%
2012 -68.370 13.64%
2013 -88.419 22.67%
2014 16.420 638.48%
2015 -491.999 103.34%
2016 -599.839 17.98%
2017 -70.001 -756.9%
2018 6.115 1244.74%
2019 -550.433 101.11%
2020 -371.572 -48.14%
2021 -573.943 35.26%
2022 -797.304 28.01%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

StemGen, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 6
2007 -15 142.86%
2008 -1 0%
2009 -1 100%
2010 -1 0%
2011 -1 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

StemGen, Inc. Free Cashflow
Year Free Cashflow Growth
2006 -93.879
2007 -90.000 -4.31%
2008 -40.000 -125%
2009 -75.350 46.91%
2010 -30.226 -149.29%
2011 -37.697 19.82%
2012 -18.861 -99.87%
2013 5.495 443.24%
2014 -122.760 104.48%
2015 -107.419 -14.28%
2016 -451.803 76.22%
2017 7.547 6086.52%
2018 -8.135 192.77%
2019 -105.091 92.26%
2020 -36.525 -187.72%
2021 -141.196 74.13%
2022 -144.146 2.05%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

StemGen, Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -93.879
2007 -90.000 -4.31%
2008 -40.000 -125%
2009 -75.350 46.91%
2010 -30.226 -149.29%
2011 -37.697 19.82%
2012 -18.861 -99.87%
2013 5.495 443.24%
2014 -122.760 104.48%
2015 -107.419 -14.28%
2016 -451.803 76.22%
2017 7.547 6086.52%
2018 -8.135 192.77%
2019 -105.091 92.26%
2020 -36.525 -187.72%
2021 -141.196 74.13%
2022 -144.146 2.05%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

StemGen, Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

StemGen, Inc. Equity
Year Equity Growth
2006 1.144.270
2007 -30.000 3914.23%
2008 -70.000 57.14%
2009 -186.191 62.4%
2010 -241.392 22.87%
2011 -240.436 -0.4%
2012 -288.806 16.75%
2013 -313.340 7.83%
2014 80 391775%
2015 -240.614 100.03%
2016 -840.453 71.37%
2017 -910.454 7.69%
2018 -904.339 -0.68%
2019 -869.799 -3.97%
2020 -1.093.571 20.46%
2021 -1.334.014 18.02%
2022 -1.736.204 23.16%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

StemGen, Inc. Assets
Year Assets Growth
2006 1.178.263
2007 10.000 -11682.63%
2008 698 -1332.66%
2009 348 -100.57%
2010 122 -185.25%
2011 2.425 94.97%
2012 564 -329.96%
2013 840 32.86%
2014 80 -950%
2015 0 0%
2016 635 100%
2017 635 0%
2018 0 0%
2019 390.201 100%
2020 397.113 1.74%
2021 401.643 1.13%
2022 140.436 -186%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

StemGen, Inc. Liabilities
Year Liabilities Growth
2006 33.993
2007 40.000 15.02%
2008 80.000 50%
2009 186.539 57.11%
2010 241.514 22.76%
2011 242.861 0.55%
2012 289.370 16.07%
2013 314.180 7.9%
2014 0 0%
2015 240.614 100%
2016 841.088 71.39%
2017 911.089 7.68%
2018 904.339 -0.75%
2019 1.260.000 28.23%
2020 1.490.684 15.48%
2021 1.735.657 14.11%
2022 1.876.640 7.51%

StemGen, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.01
Price to Earning Ratio
-7.95x
Price To Sales Ratio
117.11x
POCF Ratio
-32.3
PFCF Ratio
-32.35
Price to Book Ratio
-3.42
EV to Sales
131.51
EV Over EBITDA
-39.02
EV to Operating CashFlow
-36.33
EV to FreeCashFlow
-36.33
Earnings Yield
-0.13
FreeCashFlow Yield
-0.03
Market Cap
0,00 Bil.
Enterprise Value
0,01 Bil.
Graham Number
0.09
Graham NetNet
-0.04

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.33
ROE
0.47
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
3.59
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0.42
Return on Tangible Assets
-1.43
Days Sales Outstanding
0
Days Payables Outstanding
2024.45
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.18
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
-0,03
Tangible Book Value per Share
-0.03
Shareholders Equity per Share
-0.03
Interest Debt per Share
0.02
Debt to Equity
-0.42
Debt to Assets
1.4
Net Debt to EBITDA
-4.27
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
-0.42
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
-9400
Debt to Market Cap
0.12

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

StemGen, Inc. Dividends
Year Dividends Growth

StemGen, Inc. Profile

About StemGen, Inc.

StemGen, Inc. engages in the community offering and management of online competitions in the motorsports arena. The company offers a virtual to real platform in the motorsports industry. StemGen, Inc. is based in Angleton, Texas.

CEO
Mr. Simon Dawson
Employee
1
Address
1 Performance Drive
Angleton, 77515

StemGen, Inc. Executives & BODs

StemGen, Inc. Executives & BODs
# Name Age
1 Mr. Erik Stroman
Executive Vice President of Sales, Marketing & Business Development
70
2 Mr. Simon Dawson
Chairman, President, Secretary, Treasurer & Chief Executive Officer
70
3 Mr. Ron McNair
Chief Financial Officer
70
4 Ms. Barbara J. Burns
Chief Communications Officer & Group PR
70
5 Mr. Sean Tabatabai
Chief Strategy Officer
70
6 Mr. Ian Dawson
Senior Vice President of Partner Relations
70

StemGen, Inc. Competitors